Secondary lymphedema typically develops after cancer surgery, particularly when lymph nodes are removed or irradiated as part of treatment for breast cancer, melanoma, or gynecological malignancies. Yet clinicians have long observed something puzzling: the condition often appears months or even years after the operation, long after the surgical wound has healed. This delayed onset has led researchers to suspect that the surgery alone cannot explain the full picture, and that cancer treatments themselves, particularly chemotherapy, may quietly undermine the lymphatic vessels that drain fluid from tissues. When those vessels fail, protein-rich fluid accumulates in the limbs, causing swelling, thickening of the skin, recurrent infections, and a lasting reduction in quality of life.

The Toulouse team, led by Barbara Garmy-Susini, focused on 5-fluorouracil, or 5-FU, a first-line chemotherapeutic used against colorectal, breast, and many other cancers. In laboratory experiments, they found that 5-FU inflicts measurable damage on lymphatic endothelial cells, the specialized cells that line the inside of lymphatic vessels and coordinate their growth, maintenance, and pumping function. The drug disrupted the expression of master transcription factors that keep lymphatic vessels healthy, including GATA2, FOXC2, and SOX18, a trio of genetic regulators that act as the operational blueprint of the lymphatic system. When these genes are silenced or diminished, lymphatic vessels lose their structural integrity and their capacity to transport fluid, setting the stage for lymphedema.

The mechanism behind this damage turned out to be mitochondrial. 5-FU impaired the power plants of lymphatic endothelial cells, reducing their maximal respiration, depleting their ATP production, and eroding their spare respiratory capacity, which is the reserve a cell can call upon under stress. At the same time, mitochondria in the treated cells accumulated superoxide, a highly reactive and destructive oxygen radical. The result was a double blow: less energy to power the vessel’s contractile and barrier functions, and more oxidative stress to corrode cellular components. The researchers also observed an increase in mitochondrial mass, a compensatory response that in this context appears maladaptive, adding more dysfunctional machinery rather than repairing the existing network.

Enter metformin. Although best known as a first-line treatment for type 2 diabetes, metformin has attracted intense scientific interest in recent years for its effects on metabolism, aging, and cancer. At the molecular level, it acts as an inhibitor of complex I of the mitochondrial electron transport chain, subtly modulating how cells generate energy. That same property, the researchers discovered, is precisely what makes it protective for lymphatic vessels under chemotherapy attack. When lymphatic endothelial cells were treated with metformin alongside 5-FU, the mitochondrial damage was largely prevented: maximal respiration, ATP production, and spare respiratory capacity were restored, superoxide accumulation was blocked, and the pathological expansion of mitochondrial mass was curtailed.

The protective effect extended beyond cellular energetics to the genetic identity of the vessels themselves. Metformin restored the expression of GATA2, FOXC2, and SOX18 in cells exposed to 5-FU, effectively preserving the molecular program that defines functional lymphatic endothelium. Notably, the team found that the antioxidant effect of metformin depends on the GATA2 pathway, linking the drug’s metabolic action to the transcriptional machinery that safeguards lymphatic vessel integrity. This mechanistic connection is significant because it suggests that metformin is not merely mopping up free radicals generically, but is reinforcing a master regulatory circuit that lymphatic cells rely on to survive metabolic stress.

To test whether these cellular findings translated into living organisms, the researchers turned to mouse models. When animals received 5-FU, their lymphatic vessels collapsed, a structural failure that would be expected to impair drainage. In mice that also received metformin, this vessel collapse was not observed. The team then used a murine model of lymphedema to ask the more clinically relevant question: could metformin treat established chemotherapy-associated lymphatic damage? The answer was encouraging. Metformin reduced the limb swelling caused by 5-FU treatment, markedly decreased the reflux of lymph back into tissues, lessened the abnormal thickening of the skin, and corrected the disorganized proliferation of lymphatic vessels that characterizes the disease.

These results carry considerable weight because metformin brings an unusually favorable profile to the table. It has been used in clinical practice for decades, has a well-characterized safety record, is inexpensive, and is already taken by a large share of cancer patients who have coexisting diabetes or insulin resistance. A preventive or therapeutic strategy for lymphedema that could be delivered with an existing, orally available drug would represent a major departure from current care, which relies mainly on compression garments, manual lymphatic drainage, and, in select cases, surgical procedures such as lymphovenous anastomosis or vascularized lymph node transfer. None of these approaches reverse the underlying cellular dysfunction; they manage symptoms or reroute fluid around damaged vessels.

The study also reframes how the field thinks about lymphedema risk. If chemotherapy agents such as 5-FU can compromise lymphatic mitochondria and transcriptional programs, then the timing of interventions could shift. Rather than waiting for swelling to appear, oncologists might one day identify patients at risk and protect their lymphatic system during treatment itself. The work was supported by the European Union’s Horizon 2020 programme through the Theralymph project and by the French National Cancer Institute, reflecting a coordinated effort to bring lymphatic protection into mainstream cancer care. The researchers caution, as with any preclinical study, that mouse models do not perfectly recapitulate human disease, and clinical trials in cancer patients will be needed to establish the right dosing, timing, and patient selection before metformin can be recommended for lymphedema prevention.

Even so, the convergence of evidence is striking. A drug that inhibits complex I, restores mitochondrial respiration, suppresses superoxide, preserves GATA2-dependent gene expression, prevents vessel collapse, and reduces limb volume in vivo offers a coherent mechanistic story from molecule to organ. For the millions of cancer survivors who live with or fear lymphedema, the prospect that a decades-old diabetes pill could protect the vessels that surgery and chemotherapy put at risk is a compelling one. The Toulouse findings now provide the biological rationale to test that prospect in the clinic, and they underscore a broader lesson of modern pharmacology: some of the most valuable new applications may come from old drugs whose full range of actions we are only beginning to understand.

Subject of Research: Metformin's reversal of chemotherapy-induced lymphatic mitochondrial dysfunction and secondary lymphedema

Article Title: Metformin reverses lymphatic mitochondrial dysfunction induced by 5-FU chemotherapy

Article References: Loi, H., Draia-Nicolau, T., Balzan, E., Morfoisse, F., Lacazette, E., Prats, A.-C., & Garmy-Susini, B. (2026). Metformin reverses lymphatic mitochondrial dysfunction induced by 5-FU chemotherapy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03403-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03403-5

Keywords: metformin, lymphedema, 5-fluorouracil, chemotherapy, lymphatic endothelial cells, mitochondria, GATA2, superoxide, lymphatic vessels, drug repurposing, cancer survivors, Cell Death Discovery

Transcription factors are proteins that bind specific DNA sequences and influence which genes are read into RNA. Most act on chromatin that is already accessible, but the review emphasizes that Gata2 belongs to a special class called pioneer factors. Pioneer factors can invade condensed, chemically silenced stretches of DNA that other proteins cannot reach, prying the chromatin open and creating landing pads for the rest of the gene-regulatory machinery. In the developing embryo, this ability is what allows Gata2 to initiate the program that converts vascular cells into blood cells, a process known as the endothelial-to-hematopoietic transition, or EHT. Without Gata2, mice die around embryonic day 10.5, unable to generate the first definitive blood stem cells.

Runx1, the partner in the axis, operates on a slightly later schedule. Mouse embryos lacking Runx1 survive a day longer, dying between embryonic days 11.5 and 12.5, and the review argues that this offset in lethality reflects genuinely different temporal and tissue requirements rather than a simple hierarchy between the two factors. Runx1 is indispensable for the moment when hemogenic endothelial cells lining the dorsal aorta physically transform into hematopoietic cells, forming intra-aortic clusters that seed the future blood system. Once blood stem cells are established in the adult, however, the picture changes: Gata2 becomes the guardian of stem cell maintenance and survival, while Runx1 is more involved in driving differentiation, particularly along the megakaryocyte lineage, and in restraining stem cell quiescence programs.

The technical heart of the review lies in how these two factors remodel the three-dimensional genome. DNA in the nucleus is not a linear string; it is folded into loops and organized into topologically associating domains, or TADs, within which enhancers preferentially contact their target genes. Runx1 participates in reshaping these domains and in modulating enhancer-promoter interactions, recruiting effector proteins such as the chromatin remodeler CHD7 and the TET family of DNA demethylating enzymes. CHD7, according to work the review highlights, provides a kind of braking mechanism on hematopoietic differentiation, ensuring that Runx1-bound loci are prepared but not prematurely activated. Meanwhile, TET enzymes convert 5-methylcytosine to 5-hydroxymethylcytosine, actively erasing DNA methylation marks at genes that must be switched on for blood development.

One of the most conceptually interesting sections concerns the Runx1 +23 enhancer, a highly conserved intronic regulatory element that functions as a super-enhancer, a dense cluster of enhancer sequences bound by unusually high levels of transcriptional machinery. This element integrates inputs from Gata, Ets, and SCL transcription factor families to trigger Runx1 expression at precisely the moment HSCs must emerge. The authors describe a feed-forward loop in which Gata2 acts as the initiator, opening chromatin at such enhancers so that Runx1 and its cofactors can bind and consolidate the program. Cooperation and competition between the two factors, they argue, are not rival descriptions of the axis but different behaviors at different classes of regulatory element, with redundancy that is directional, dose-graded, and even species-dependent, as zebrafish and mouse studies demonstrate.

When this finely tuned system breaks, the consequences are catastrophic, and the review frames them under the vivid concept of epigenetic addiction. Myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes, frequently arise not from mutations in the coding sequence of Runx1 or Gata2 themselves but from disruptions to the epigenetic architecture they maintain. Hypermethylation of regulatory DNA can silence the axis; haploinsufficiency, the loss of one functional copy of Gata2, destabilizes chromatin looping and predisposes carriers to immunodeficiency, bone marrow failure, and leukemia; and enhancer hijacking can rewire the genome entirely. A famous example cited in the literature is a single oncogenic enhancer rearrangement that simultaneously deregulates EVI1 and GATA2, driving an aggressive leukemia with one structural change.

The three-dimensional view of leukemia is reinforced by studies of the cohesin complex, the ring-shaped protein assembly that physically anchors chromatin loops. Mutations in cohesin components such as STAG2, combined with RUNX1 deficiency, synergistically perturb chromatin looping and produce myelodysplastic syndromes. Cohesin mutants appear to lock cells into a stem-cell-like program by altering chromatin accessibility in ways that mimic, and corrupt, the pioneer-factor landscape that Gata2 normally curates. GATA2 has even been shown to perform mitotic bookmarking, preserving regulatory memory through cell division, and to decommission enhancers that would otherwise amplify inflammatory signaling, a newly appreciated mechanism constraining inflammation in hematopoietic progenitors.

What elevates the review beyond a descriptive synthesis is its treatment of therapy. Because malignant clones in AML and MDS are epigenetically addicted to their distorted chromatin states, the authors argue, those states are also therapeutic vulnerabilities. Existing demethylating agents, such as hypomethylating drugs used in myelodysplastic syndromes, exploit this dependence by partially reversing aberrant methylation. More futuristic approaches include CRISPR-Cas9-mediated epigenetic editing, in which programmable molecular tools are directed to specific enhancers to rewrite their histone marks or methylation status without cutting the DNA, and super-enhancer targeting, which aims to collapse the transcriptional hubs that sustain oncogenic programs such as RUNX1-driven T-cell leukemia. The goal in every case is the same: restore proper chromatin architecture to the malignant clone and return it to a controllable state.

The timing of such interventions matters enormously, and the review is careful about dose. Both too little and too much GATA2 are harmful; enforced overexpression blocks normal hematopoiesis, while low-level overexpression promotes myeloid progenitor self-renewal at the expense of lymphoid differentiation. Similarly, Runx1 isoforms show differential expression during development yet overlapping functions in adult stem cells, and DNA methylation of Runx1 regulatory regions correlates with the transition from primitive to definitive blood potential. Any therapeutic strategy that manipulates the axis must therefore respect the narrow dosage window within which healthy hematopoiesis operates, a constraint the authors treat as a central design principle rather than a footnote.

For a field increasingly populated by single-cell atlases, the review also points to methodological frontiers. Techniques such as single-cell RNA sequencing, single-cell ATAC-seq for chromatin accessibility, and new platforms that jointly profile multiple epigenetic proteins and transcription in the same cell are making it possible to watch the Runx1-Gata2 axis operate in individual cells as they commit to fate. Combined with barcoding technologies that trace the real-life fates of hematopoietic stem cells in vivo, these tools are converting what was once a static network diagram into a dynamic, quantifiable choreography. The Runx1-Gata2 axis, as Mallick and Chakraborty present it, is best understood not as a pair of genes but as an epigenetic operating system, one whose architecture, when faithfully maintained, builds the blood, and whose corruption, when left unrepaired, builds leukemia.

Subject of Research: Epigenetic regulation of hematopoietic lineage fate by the Runx1-Gata2 transcription factor axis

Article Title: The Runx1-Gata2 axis: epigenetic architecture of lineage fate

Article References: Mallick, S., & Chakraborty, A. (2026). The Runx1-Gata2 axis: epigenetic architecture of lineage fate. Molecular Biology Reports, 53(1), Article 1643. https://doi.org/10.1007/s11033-026-12742-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12742-6

Keywords: Runx1, Gata2, epigenetics, hematopoietic stem cells, chromatin, transcription factors, acute myeloid leukemia, myelodysplastic syndrome, pioneer factor, super-enhancer, TET enzymes, CRISPR epigenetic editing